Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Methocarbamol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
•
Other medicines and Methocarbamol If you are taking any of the following medicines, you should tell your doctor or pharmacist as Methocarbamol may interact with them:
are allergic to methocarbamol, or have had any problems in the past with medicines containing methocarbamol are allergic to any of the other ingredients of this medicine (listed in section 6) have ever suffered any brain damage or coma suffer from epilepsy or convulsions suffer from muscle weakness (a disease called myasthenia gravis)
Warnings and precautions Talk to your doctor or pharmacist before taking Methocarbamol. Tell your doctor or pharmacist before taking Methocarbamol if you:
Information on Sodium content This medicine contains less than 1 mmol sodium (23 mg) per filmcoated tablet, that is to say essentially 'sodium-free'.
e Methocarbamol Do not take Methocarbamol if you:
• • • •
Methocarbamol with alcohol Consumption of alcohol during methocarbamol treatment may potentiate the effect of the medicine. Do not drink alcohol while you are taking methocarbamol. Pregnancy, breast-feeding and fertility Pregnancy There is no experience available concerning the use of methocarbamol during pregnancy. The potential risk to humans is not known. You should not take methocarbamol during pregnancy.
Methocarbamol Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Adults: Take TWO tablets with a little water, FOUR times a day. Sometimes a lower dose may be sufficient. You should spread the doses as evenly as possible over a 24-hour period. Elderly: older patients may only need half the usual dose to give the same relief from the pain and muscle spasms. Children: These tablets should not be given to children Liver impairment: you may need a longer interval between taking the tablets if you have liver disease. You should always follow your doctor's instructions carefully. These tablets are for short-term treatment. Take them for as long as your doctor has recommended, or until you no longer need them to ease the pain. Return any unused tablets to your pharmacist.
Black A/s: 210 x 300 mm
Initiator Artist:
Component
Item Code
Date & Time
Leaflet
P1540169
06.10.2025 & 9:15 AM Reviewed / Approved by
Customer / Country
Version No.
Reason Of Issue
Milpham_Unit-15
01
Revision
Ramesh P
Dimensions
No. of Colours : 01
Jaya Durga
210 x 300 mm
Packaging Development Team Leader
Product Name Methocarbamol
40169
Additional Information : Supersede Item Code: P1536211
Sign / Date
Method of administration Methocarbamol is for oral use. Swallow the film-coated tablets with plenty of water. The film-coated tablets should be taken for as long as the symptoms of muscle tightness persist, but no longer than 30 days. If you take more Methocarbamol than you should Contact your doctor immediately, go or take the person to the Accident and Emergency Department of your local hospital. Always take the bottle of Methocarbamol with you, even if it is empty. If you forget to take Methocarbamol
you can help provide more information on the safety of this medicine.
Marketing Authorisation Holder Milpharm Limited 1 Roundwood Avenue Stockley Park, Uxbridge UB11 1AF United Kingdom Manufacturer APL Swift Services (Malta) Limited HF26, Hal Far Industrial Estate, Hal Far, Birzebbugia, BBG 3000, Malta Or Milpharm Limited 1 Roundwood Avenue Stockley Park, Uxbridge UB11 1AF United Kingdom Or Generis Farmacêutica, S.A., Rua João de Deus, n.o 19, Venda Nova, 2700-487 Amadora, Portugal This leaflet was last revised in 10/2025.
Methocarbamol Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The first two numbers indicate the month; the last four numbers indicate the year. The expiry date refers to the last date of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
P1540169
This medicine does not require any special storage conditions
What Methocarbamol contains The active substance is methocarbamol Each film-coated tablet contains 750 mg methocarbamol The other ingredients are: Tablet core: maize starch, sodium starch glycolate (Type – A), povidone (K-30), sodium laurilsulfate, talc and magnesium stearate Tablet coat: hypromellose 2910 (6mPas), titanium dioxide and macrogol 400.
Take your normal dose when you remember. Always leave at least 4 hours before taking any more tablets. DO NOT TAKE A DOUBLE DOSE OF TABLETS TO MAKE UP FOR A MISSED DOSE.
What Methocarbamol looks like and contents of the pack Methocarbamol 750 mg film-coated tablets are white, film coated, capsule shaped biconvex tablet, debossed with 'METT' on one side and '750' on the other side.
4. Possible side effects
Methocarbamol 750 mg film-coated tablets are supplied in a white opaque round HDPE container.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Pack sizes: 100 film-coated tablets.
If you notice any of the following rare symptoms, you should STOP taking your tablets and tell your doctor immediately:
Methocarbamol 750 mg film-coated tablets comes as tablet containing 750mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Methocarbamol 750 mg film-coated tablets is methocarbamol.
Medicines with the same active substance, strength and form include: Robaxin-750, 750 mg Film-coated Tablets, Methocarbamol 750 mg film coated-Tablet, Methocarbamol 750 mg tablets. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Methocarbamol 750 mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Symptomatic treatment of painful muscular tension, especially in the lower back (lumbago)
Methocarbamol is indicated in adults
Posology
Adults: The usual dose is 2 tablets four times daily but therapeutic response has been achieved with doses as low as 1 tablet three times daily.
Elderly: Half the maximum dose or less may be sufficient to produce a therapeutic response.
Paediatric population
Not recommended.
Hepatically impaired
In patients with chronic hepatic disease the elimination half-life may be prolonged. Therefore, consideration should be given to increasing the dose interval.
Method of administration
For oral use.
Take the film-coated tablets with sufficient water.
Hypersensitivity to methocarbamol or to any of the excipients listed in section 6.1.
• Coma or pre-coma states
• Central nervous system disorders
• Myasthenia gravis
• Patients with a tendency to epileptic cramps
Methocarbamol should be used with caution in patients with renal and hepatic insufficiency.
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.
Interference with laboratory tests
Methocarbamol may cause colour interference in certain screening tests for 5-hydroxyindolacetic acid (5-HIAA) and vanillylmandelic acid (VMA)
If methocarbamol is used concomitantly with centrally acting drugs such as barbiturates, opioids and appetite suppressants, the effects can be mutually enhanced.
The consumption of alcohol during treatment with methocarbamol can increase the effect.
The effects of anticholinergics, such as atropine and some psychotropic drugs, may be potentiated by methocarbamol.
Methocarbamol may reduce the effect of pyridostigmine bromide. Therefore, methocarbamol should not be used by patients with myasthenia gravis, particularly those being treated with pyridostigmine.
Pregnancy
There is no experience with the use of methocarbamol during pregnancy .There are no data from animal studies related to effects on pregnancy , embryonal/foetal development, parturition and postnatal development ( see section 5.3). the potential risk for humans is unknown. Therefore methocarbamol should not be used during pregnancy.
Breastfeeding
It is not known whether methocarbamol and/or its metabolites are excreted in human milk. Methocarbamol and/or its metabolites are excreted in the milk of lactating dogs Methocarbamol should therefore not be used during breastfeeding.
Fertility
No data are available on the influence of methocarbamol on human fertility.
Methocarbamol has moderate influence on the ability to drive and to use machines. Methocarbamol can cause dizziness or drowsiness, especially if other medicines that can also cause drowsiness are being taken at the same time..
Patients should be advised not to perform these activities if they experience dizziness or drowsiness.
The frequency information on side effects is based on the following categories (where it has been possible to obtain frequency data from the literature):
Very common ≥ 1/10
Common ≥ 1/100 to < 1/10
Uncommon ≥ 1/1,000 to < 1/100
Rare ≥ 1/10,000 to < 1/1,000
Very rare < 1/10,000
Not known The frequency cannot be estimated from the available data
The following adverse reactions have been reported with the use of methocarbamol:
System organ class
Frequency according to MedDRA convention
Rare
Very rare
Not known
Infections and infestations
Conjunctivitis
Immune system disorders
Anaphylactic reaction
Metabolism and nutrition disorders
Decreased appetite
Psychiatric disorders
Restlessness, anxiety, confusion
Nervous system disorders
Headache, dizziness, metallic taste
Syncope, nystagmus, drowsiness,, tremor, seizure
Somnolence, coordination disorder,
Hypoesthesia*,
Paresthesia*
Eye disorders
Visual impairment, double vision
Cardiac disorders
Bradycardia
Vascular disorders
Hypotension
Hot flush
Respiratory, thoracic and mediastinal disorders
Swelling of nasal mucosa
Gastrointestinal disorders
Nausea, vomiting
Nausea, diarrhoea
Skin and subcutaneous tissue disorders
Angioedema, rash, pruritus, urticaria
General disorders and administration site conditions
Fever
Fatigue
*Localized, transient sensory disturbance primarily affecting the head (e.g. face, scalp), the mouth region (e.g. lips, tongue) or the extremities (hands, fingers, feet)
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures and coma. One adult survived the deliberate ingestion of 22 to 30 grams of methocarbamol without serious toxicity. Another adult survived a dose of 30 to 50 grams. The principal symptom in both cases was extreme drowsiness. Treatment was symptomatic and recovery was uneventful. However, there have been cases of fatal overdose.
Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of haemodialysis in managing overdose is unknown.
Ask anything about Methocarbamol 750 mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.